Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen [10]

AIDS

Volumn 21, Issue 2, 2007, Pages 268-269

  Pavel, Simona ^a   Burty, Christine ^b   Alcaraz, Isabelle ^a   De La Tribonnière, Xavier ^a   Baclet, Véronique ^a   Ajana, Faiza ^a   Mouton, Yves ^a   Rabaud, Christian ^b   Yazdanpanah, Yazdan ^a,c,d  

^a CENTRE HOSPITALIER DE TOURCOING   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c UNIV LILLE   (France)

^d IESEG School of Management   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; DOXYCYCLINE; FOSAMPRENAVIR PLUS RITONAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ABDOMINAL PAIN; CLINICAL FEATURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LABORATORY TEST; LETTER; LIVER TOXICITY; NAUSEA; OCCUPATIONAL EXPOSURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; VACCINATION; VOMITING;

EID: 33845917730     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328011aa35     Document Type: Letter

References (11)

1. Circulaire DGS/DHOS/DRT/DSS no. 2003/165 du 2 Avril 2003: relating to the recommendations for the implementation of an antiretroviral treatment after exposure to the risk of transmission of HIV or other biological liquids at the time of care [in French]. Bull Epidemiol Hebdom 25/98.
2. Puro V, Soldani F, De Carli G, Lazarevic Z, Mattioli F, Ippolito G. Drug-induced aminotransferase alterations during antiretroviral HIV post-exposure prophylaxis. AIDS 2003; 17:1988-1990.
3. Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures worldwide, 1997-2000. MMWR 2001; 49:1153-1156.
4. Rabaud C, Burty C, Valle C, Christian B, Penalba C, Prazuck T, et al. Post-exposure prophylaxis of HIV infection: comparison of tolerability of 4 PEP regimens. In: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5-8 February 2006 [Poster 905].
5. Rabaud C, Bevilacqua S, Beguinot I, Dorvauz V, Schumacher H, May T, Canton P. Tolerability of post-exposure zidovudine + lamivudine + nelfinavir prophylaxis of HIV infection. Clin Infect Dis 2001; 32:1494-1495.
6. Rabaud C, Burty C, Grandidier M, Christian B, Penalba C, Beguinot I, et al. Tolerability of post-exposure prophylaxis of HIV infection with the combination of zidovudine/lamivudine and lopinavir/ritonavir (Combivir® + Kaletra®). Clin Infect Dis 2005; 40:303-305.
7. Rabaud C, Valle C, Prazuck T, Christian B, Grandidier M, Beguinot I, et al. Tolerability of post-exposure prophylaxis of HIV infection with the combination of zidovudine/lamivudine + tenofovir. In: XVth International AIDS Conference. 11-16 July 2004, Bangkok, Thailand [Abstract TuPeB4647].
8. Burty C, Christian B, Pouaha J, Penalba CH, Chavanet P, Prazuck TH, et al. Tolerability of post-exposure prophylaxis of HIV infection with the combination of lamivudine + tenofovir + atazanavir boosted with by ritonavir (LTA/r). In: 25th Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse (RICAI). Paris, France, December 2005 [Abstr. No. 92/230].
9. Rodriguez-French A, Boghossian J, Gray EG, Nadler JP, Quinones AR, Sepulveda GE, et al. The NEAT Study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2004; 35:22-32.
10. Gathe JC, Ive P, Wood R, Schurmann D, Bellos NC, DeJesus E, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004; 18:1529-1537.
11. Shelthon MJ, Wire MB, Lou Y, Adamkiewicz B, Min SS. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir. Antimicrob Agents Chemother 2006; 50:928-934.